

AMENDMENTS TO THE CLAIMS

1-34. (canceled)

35. (original) A pharmaceutical composition comprising:

a therapeutically effective amount of cilostazol;

a solubilizer; and

a release modulator;

wherein the release of cilostazol and solubilizer are synchronized.

36. (currently amended) The pharmaceutical composition of claim 35, wherein the solubilizer is a polyoxyethylene-polyoxypropylene block copolymer, a polysaccharide-based polymerecyclodextrin or cyclodextrin derivative, a fatty acid or fatty acid esterderivative, a tocol, derivative, racemers, enantiomers, or mixtures thereof.

37. (currently amended) The pharmaceutical composition of claim 36, wherein the tocol is a tocol derivative is selected from the group consisting of an α -tocopherol ester, a polyethoxylated α -tocopherol ester, racemers, enantiomers, or mixtures thereof.

38. (currently amended) The pharmaceutical composition of claim ~~37~~36, wherein the tocol is a tocol derivative is selected from the group consisting of α -tocopherol, α -tocopherol acetate, α -tocopherol ~~nicotinate~~nicotinate, α -tocopherol succinate, α -tocopherol polyethyleneglycol succinate, α -tocopherol polyethyleneglycol (200-8000) succinate, α -tocopherol polyethyleneglycol 400 succinate, α -tocopherol polyethylene glycol 1000 succinate, d- α -

tocopherol polyethylene glycol 1000 succinate, dl- α -tocopherol polyethylene glycol 1000 succinate, racemers, enantiomers, or mixtures thereof.

39. (currently amended) The pharmaceutical composition of claim 36, wherein the fatty acid ~~or fatty acid derivative~~ is an ester with glycerol, propylene glycol, sorbitol, sucrose, glucose, polyethylene glycol, an alpha-hydroxy acid or mixtures thereof.

40. (currently amended) The pharmaceutical composition of claim 39, wherein the fatty acid ester is a polyoxyl castor oil derivative, a PEG-8 caprylic/capric glyceride, a polysorbate, sorbitan monooleate, a medium chain mono-, di-, or triglyceride, an acetylated monoglyceride, a linoleoyl macroglyceride, a lauroyl macrogol-32 glyceride or mixtures thereof.

41. (currently amended) The pharmaceutical composition of claim 39, wherein the fatty acid ester is polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-8 caprylic/capric glycerides, sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, glyceryl mono/dioleate, glyceryl caprylate/caprate, caprylic acid mono/diglycerides, mono- and diacetylated monoglycerides, linoleoyl macroglycerides, ~~caprylocaproyl macroglycerides~~, lauroyl macrogol-32 glycerides, propylene glycol monolaurate, propylene glycol monocaprylate.

42. (currently amended) The pharmaceutical composition of claim 35, wherein the release modulator is an osmotic pump, a ~~slowly~~ dissolving salt ~~of a~~ or complex, an erodible matrix, an ion exchange resin, a wax, an insoluble carrier, a polymeric matrix, a polymeric coating, a fatty

alcohol, ~~a fatty alcohol derivative, a fatty acid, or fatty acid derivative~~ or a tocol derivative,
racemers, enantiomers, or mixtures thereof.

43. (currently amended) The pharmaceutical composition of claim 42, wherein the release modulator is a polymeric matrix, a polymeric coating, a wax, a fatty alcohol, ~~a fatty alcohol derivative, a fatty acid or fatty acid derivative~~, a tocol, derivative, racemers, enantiomers, or mixtures thereof.

44. (currently amended) The pharmaceutical composition of claim 43, wherein the polymeric matrix or polymeric coating is a cellulose ~~derivative~~, an acrylic polymer, a polyvinylpyrrolidone copolymer, a shellac, polyvinyl acetyl phthalate, a ~~high molecular weight polysaccharide gum~~ or mixtures thereof.

45. (currently amended) The pharmaceutical composition of claim 43, wherein the tocol is a tocol derivative ~~is selected from the group consisting of~~ α -tocopherol, α -tocopherol acetate, α -tocopherol ~~nicotinate~~nicotinate, α -tocopherol succinate, α -tocopherol polyethyleneglycol succinate, α -tocopherol polyethylene glycol 400 succinate, racemers, enantiomers, or mixtures thereof.

46. (currently amended) The pharmaceutical composition of claim 43, wherein the release modulator is microcrystalline wax, hydrogenated vegetable oil, glycerol dibehenate, glycerol distearate, glycerol dipalmitate, glycerol palmitostearate, a cellulose ~~derivative~~, a lauroyl macrogol-32 glyceride, a stearyl macrogol-32 glyceride, calcium steroyl lactylate, stearic acid,

stearoyl alcohol, sucrose distearate, sucrose palmitate, sucrose dipalmitate, sorbitan monooleate, yellow wax, white wax, nonionic emulsifying wax, carnauba wax, microcrystalline wax, cetyl ester wax or mixtures thereof.

47. (original) The pharmaceutical composition of claim 35, wherein the release is controlled over an extended period of time.

48. (original) The pharmaceutical composition of claim 47, wherein the period of time is more than about 1 hour.

49. (original) The pharmaceutical composition of claim 48, wherein the period of time is more than about 2 hours.

50. (currently amended) The pharmaceutical composition of claim 49, wherein the period of time is ~~between~~from about 2 hours ~~and to~~ about 24 hours.

51. (original) The pharmaceutical composition of claim 35, wherein the release of cilostazol and solubilizer are synchronized with a correlation coefficient of greater than about 0.80.

52. (original) The pharmaceutical composition of claim 35 including one or more additives.

53. (currently amended) The pharmaceutical composition of claim 35 in which the amount of solubilizer is from about 15% w/w to about 95% w/w of the composition, the amount of release

modulator is from about 1% to about 50% w/w of the composition, and the amount of cilostazol is from about 0.5% to about 50% w/w of the composition.

54. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is d- α -tocopherol polyethylene glycol 1000 succinate and the release modulator is α -tocopherol succinate.

55. (original) The pharmaceutical composition of claim 54 including one or more additives.

56. (original) The pharmaceutical composition of claim 55, wherein the solubilizer is d- α -tocopherol polyethylene glycol 1000 succinate, the release modulator is α -tocopherol succinate and the additive is polyethylene glycol.

57. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is hydroxypropylmethylcellulose.

58. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is glycerol dibehenate, glycerol palmitostearate, glycerol distearate, or mixtures thereof.

59. (original) An oral dosage form comprising:
a therapeutically effective amount of cilostazol;
a solubilizer; and

a release modulator;

wherein the release of cilostazol and solubilizer are synchronized.

60. (original) A solid oral dosage form comprising:

a therapeutically effective amount of cilostazol;

a solubilizer; and

a release modulator;

wherein the release of cilostazol and solubilizer are synchronized.

61. (original) The dosage form of claim 60, wherein the dosage form is a capsule.

62. (new) The pharmaceutical composition of claim 36, wherein the polysaccharide-based polymer is selected from the group consisting of maltodextrins, dextrates, cyclodextrins, and mixtures thereof.

63. (new) The pharmaceutical composition of claim 62, wherein the polysaccharide-based polymer is a cyclodextrin.

64. (new) The pharmaceutical composition of claim 63, wherein the cyclodextrin is a cyclodextrin derivative selected from the group consisting of sulfobutyl ethers, hydroxypropyl ethers, and mixtures thereof.